<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The purpose of the trial was to examine the effects of <z:chebi fb="0" ids="2618">amantadine</z:chebi>, a <z:chebi fb="0" ids="31882">N-methyl-D-aspartate</z:chebi> (<z:chebi fb="0" ids="31882">NMDA</z:chebi>) <z:chebi fb="68" ids="48706">antagonist</z:chebi>, on the oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test (OGTT) plus insulin, glucagon and <z:chebi fb="65" ids="25512">neurotransmitters</z:chebi> circulating levels </plain></SENT>
<SENT sid="1" pm="."><plain>Previous findings showed that <z:mp ids='MP_0002079'>hyperinsulinism</z:mp> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> are positively associated with neural sympathetic and adrenal sympathetic activities, respectively </plain></SENT>
<SENT sid="2" pm="."><plain>These peripheral sympathetic branches depend on the pontine (A(5)-noradrenergic) and the rostral ventrolateral (C(1)-adrenergic) medullary nuclei </plain></SENT>
<SENT sid="3" pm="."><plain>They are excited by <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> axons which act at <z:chebi fb="0" ids="31882">NMDA</z:chebi> postsynaptic receptors </plain></SENT>
<SENT sid="4" pm="."><plain>RESEARCH DESIGN AND METHODS: One OGTT plus placebo and one OGTT plus oral <z:chebi fb="0" ids="2618">amantadine</z:chebi> test were carried out two weeks apart in 15 caucasic <z:mpath ids='MPATH_458'>normal</z:mpath> voluntary humans </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="15" ids="33569">Noradrenaline</z:chebi>, <z:chebi fb="47" ids="28918,33568">adrenaline</z:chebi>, <z:chebi fb="40" ids="18243">dopamine</z:chebi>, plasma-free <z:chebi fb="19" ids="28790">serotonin</z:chebi>, platelet <z:chebi fb="19" ids="28790">serotonin</z:chebi>, <z:chebi fb="105" ids="17234">glucose</z:chebi>, glucagon, and insulin were measured throughout the 180-minute testing period </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Maximal reductions of plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> and glucagon plus exacerbated insulin rises were significantly greater throughout the oral <z:chebi fb="105" ids="17234">glucose</z:chebi> plus <z:chebi fb="0" ids="2618">amantadine</z:chebi> test than those registered throughout the oral <z:chebi fb="105" ids="17234">glucose</z:chebi> plus placebo challenge </plain></SENT>
<SENT sid="7" pm="."><plain>The above findings were paralleled by greater than <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="15" ids="33569">noradrenaline</z:chebi>/<z:chebi fb="47" ids="28918,33568">adrenaline</z:chebi> plasma ratio increases </plain></SENT>
<SENT sid="8" pm="."><plain>In addition, maximal reductions of the platelet <z:chebi fb="19" ids="28790">serotonin</z:chebi> and plasma <z:chebi fb="19" ids="28790">serotonin</z:chebi> circulating values contrasted with the <z:mpath ids='MPATH_458'>normal</z:mpath> rises of these parameters, always registered during the <z:chebi fb="105" ids="17234">glucose</z:chebi> load plus placebo challenge </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: This study supports the theory that <z:chebi fb="0" ids="2618">amantadine</z:chebi> might be a powerful <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> tool and could be added to the therapeutic arsenal against type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>